Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)
Hong Kong
· Delayed Price · Currency is HKD | Market Cap | 32.10B |
| Revenue (ttm) | 1.53B |
| Net Income (ttm) | 192.74M |
| Shares Out | 446.90M |
| EPS (ttm) | 0.48 |
| PE Ratio | 94.42 |
| Forward PE | 54.56 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,753,982 |
| Average Volume | 1,268,404 |
| Open | 44.02 |
| Previous Close | 45.18 |
| Day's Range | 44.02 - 55.10 |
| 52-Week Range | 8.04 - 63.00 |
| Beta | 0.32 |
| RSI | 62.25 |
| Earnings Date | Mar 27, 2026 |
About HKG:2315
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People’s Republic of China, the United States, and internationally. It operates through five segments: Gene-editing services, Pre-clinical pharmacology and efficacy evaluation, Animal models selling, Antibody development, and Innovative drugs development. The Gene-editing services segment provides the customized gene editing services based on animals as well as c... [Read more]
News
Strengthening Translational Research in India: GVSAP and Biocytogen Expand Collaboration
Business Wire India GV Safety Assessment Platform (GVSAP), an integrated preclinical R&D enabler within the GVRP portfolio, today announced an...
Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions
BEIJING — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovativ...
Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website
Business Wire India Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with...
Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development
BEIJING — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovativ...
Biocytogen Responds to Harbour BioMed’s Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing
BEIJING — In response to Harbour BioMed’s recent press release regarding a procedural development in their ongoing legal claim, Biocytogen issues the following statement: Biocytogen stands by its core...
Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform
Beijing, China: Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315) today announced that the key technology of its independently developed RenMab™fully human antibody mouse platfo...
Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009)
BEIJING & NANJING, China — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (“NJCTTQ”) announced that NTB003 (formerly ...
Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors
Collaboration initiates development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs) Biocytogen’s RenLite® meets Acepodia’s AD2C for precision oncology solutions BEIJING & ALAMEDA, Calif....